The clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centers

Basit Öğe Kaydı
dc.authoridAkbay, Fatih/0000-0002-4263-1391
dc.authorwosidAkbay, Fatih/AAA-2243-2022
dc.contributor.authorPamuk, O. N.
dc.contributor.authorAkbay, F. G.
dc.contributor.authorDoenmez, S.
dc.contributor.authorYilmaz, N.
dc.contributor.authorCalayir, G. B.
dc.contributor.authorYavuz, S.
dc.date.accessioned2024-06-12T11:15:57Z
dc.date.available2024-06-12T11:15:57Z
dc.date.issued2013
dc.departmentTrakya Üniversitesien_US
dc.description.abstractBackground Systemic lupus erythematosus (SLE) is a systemic autoimmune disease with a variety of clinical features. Survival has become longer as a result of better treatment modalities and better supportive care. There is no information on survival of SLE patients in Turkey. We evaluated clinical features and survival in SLE patients in two rheumatology departments. Methods All SLE patients being followed up by the Department of Rheumatology, Trakya University Medical Faculty, and the Department of Rheumatology, Marmara University Medical Faculty, over the 1996-2012 period were included. Patients were diagnosed with SLE if they fulfilled at least four American College of Rheumatology (ACR) criteria. The clinical and laboratory features, mortality data were obtained from medical charts. Results We had 428 SLE patients, and women (399 patients, 93.2%) far outnumbered men (29 patients, 6.8%). The mean age at the time of SLE diagnosis was 40.312.4 years. The most frequent clinical manifestations were arthritis (76.9%) and photosensitivity (70.1%). Renal disease was present in 32.9% of patients and neurological involvement in 12.9% of patients. After a median follow-up of 60 months, 19 patients died. The most frequent causes of death were ischemic heart disease, chronic renal failure and sepsis. The rate of five-year survival was 96%; 10-year survival, 92%; and 15-year survival, 88.8%. Multivariate Cox analysis showed that serositis at the time of diagnosis, SLE disease activity index (SLEDAI) score 6, and autoimmune hemolytic anemia were independent prognostic factors. Conclusions Data from two centers in Northwestern Turkey show that the mortality rate for SLE is similar to the rate in Western countries.en_US
dc.identifier.doi10.1177/0961203313499956
dc.identifier.endpage1424en_US
dc.identifier.issn0961-2033
dc.identifier.issn1477-0962
dc.identifier.issue13en_US
dc.identifier.pmid23929639en_US
dc.identifier.scopus2-s2.0-84887071646en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage1416en_US
dc.identifier.urihttps://doi.org/10.1177/0961203313499956
dc.identifier.urihttps://hdl.handle.net/20.500.14551/24138
dc.identifier.volume22en_US
dc.identifier.wosWOS:000326011800015en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSage Publications Ltden_US
dc.relation.ispartofLupusen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectSystemic Lupus Erythematosusen_US
dc.subjectSurvivalen_US
dc.subjectPrognosisen_US
dc.subjectNephritisen_US
dc.subjectPrimary Antiphospholipid Syndromeen_US
dc.subjectAccelerated Atherosclerosisen_US
dc.subjectRevised Criteriaen_US
dc.subjectMortalityen_US
dc.subjectClassificationen_US
dc.subjectPopulationen_US
dc.subjectPrevalenceen_US
dc.subjectIndexen_US
dc.subjectRaceen_US
dc.subjectSleen_US
dc.titleThe clinical manifestations and survival of systemic lupus erythematosus patients in Turkey: report from two centersen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu